DELAFIELD, Wis. (Stockpickr) -- There isn't a day that goes by on Wall Street when certain stocks trading for $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and solid risk management are banking ridiculous coin on a regular basis.

Just take a look at some of the monster movers to the upside in the under-$10 complex from Wednesday, including IDI (IDI) , which ripped large to the upside by 25.8%; Solar3D (SLTD) , which soared higher by 22.8%; CVSL (CVSL) , which trended up big by 19.8%; and MoSys (MOSY) - Get Report, which surged by 17.6%. You don't even have to catch the entire move in lower-priced stocks such as these to make outsized returns when trading.

Low-priced stocks are something that I tweet about on a regular basis. I frequently flag high-probability setups, breakout candidates and low-priced stocks that are acting technically bullish. I like to hunt for low-priced stocks that are showing bullish price and volume trends, since that increases the probability of those stocks heading higher. These setups often produce monster moves higher in very short time frames.

When I trade under-$10 names, I do it almost entirely based off of the charts and technical analysis. I also like to find under-$10 names with a catalyst, but that's secondary to the chart and volume patterns.

With that in mind, here's a look at several stocks under $10 that look poised to potentially trade higher from current levels.

TrovaGene

Image placeholder title

One under-$10 molecular diagnostic player that's starting to spike within range of triggering a big breakout trade is TrovaGene (TROV) - Get Report, which focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. This stock has been on fire over the last six months, with shares exploding to the upside by 71.1%.

If you take a glance at the chart for TrovaGene, you'll see that this stock has been attempting to carve out a near-term bottom over the last month or so, with shares finding buying interest at $8.58, $9.10 and $8.86 a share. Shares of TrovaGene ripped to the upside on Wednesday back above its 20-day moving average of $9.64 a share with strong upside volume flows. Volume for the day registered over 970,000 shares, which is well above its three-month average volume of 670,287 shares. That strong move is now quickly pushing shares of TrovaGene within range of triggering a big breakout trade above some key near-term overhead resistance levels.

Market players should now look for long-biased trades in shares of TrovaGene if it manages to break out above some near-term overhead resistance levels at $10.40 to $10.46 a share and then above its 50-day moving average of $10.72 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 670,287 shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $13 to its 52-week high of $13.58 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right below $9 a share or around its range lows of $8.86 to $8.58 a share. One can also buy shares of TrovaGene off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Nexvet Biopharma

Image placeholder title

Another under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Nexvet Biopharma (NVET) , which focuses on developing and commercializing novel, species-specific biologics based on human biologics for companion animals. This stock has been hammered lower by the sellers over the last three months, with shares off sharply by 44.7%.

If you take a look at the chart for Nexvet Biopharma, you'll notice that this stock recently came out of a massive downtrend over the last five months, that saw shares of Nexvet Biopharma collapse from its February high of around $10.50 to its recent low of $4.40 a share. Following that massive downtrend, this stock has now started to stabilize and it has attempted to carve out a double bottom at $4.40 to $4.50 a share. This stock is now starting to trend back above its 20-day moving average of $4.76 and it's beginning to move within range of triggering a big breakout trade above a key downtrend line that dates back to June.

Market players should now look for long-biased trades in Nexvet Biopharma if it manages to break out above a key downtrend line that will trigger over $4.97 to just above $5 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 23,995 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $5.30 to $5.45, or even near its June high of $5.89 a share. Any high-volume move above $5.89 will then give this stock a chance to tag $6.50 to $7 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around those double bottom support levels at $4.50 to $4.40 a share. One can also buy shares of Nexvet Biopharma off strength once it starts to trend above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Aoxing Pharmaceutical

Image placeholder title

One under-$10 specialty pharmaceutical player that's starting to spike within range of triggering a big breakout trade is Aoxing Pharmaceuticals (AXN) , which researches, develops, manufactures, and distributes various narcotic, pain-management and addiction treatment pharmaceutical products primarily in the People's Republic of China. This stock has exploded to the upside over the last six months, with shares up huge by 371.4%.

If you take a glance at the chart for Aoxing Pharmaceuticals, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $1.17 to its recent high of $1.90 a share. During that uptrend, shares of Aoxing Pharmaceutical have been consistently making higher lows and higher highs, which is bullish technical price action. That strong trend to the upside in the short-term has now pushed this stock within range of triggering a big breakout trade above some key near-term overhead resistance levels.

Traders should now look for long-biased trades in Aoxing Pharmaceuticals if it manages to break out above its 50-day moving average of $1.75 a share and then above more key resistance at $1.90 to $1.93 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.01 million shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels $2.27 to $2.60 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at $1.50 to $1.45 a share. One can also buy shares of Aoxing Pharmaceuticals off strength once it starts to bust above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Lion Biotechnologies

Image placeholder title

Another under-$10 clinical-stage biopharmaceutical player that's starting to spike within range of triggering a major breakout trade is Lion Biotechnologies (LBIO) , which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. This stock has been under selling pressure over the last three months, with shares trending to the downside by 20.8%.

If you look at the chart for Lion Biotechnologies, you'll see that this stock has been uptrending a bit over the last month or so, with shares moving higher from its low of $8.02 to its recent high of $10.29 a share. During that uptrend, this stock has been making mostly higher lows and higher highs, which is bullish technical price action. That move has also pushed shares of Lion Biotechnologies back above both its 200-day and 20-day moving averages. This stock is now starting to trend rapidly within range of triggering a major breakout above a key downtrend line that dates back to March.

Market players should now look for long-biased trades in Lion Biotechnologies if it manages to break out above that downtrend line which will trigger over its 50-day at $10.07 to $10.29 a share and then above about $10.70 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 743,665 shares. If that breakout gets started soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $12.50, or even $13 to $13.89 a share.

Traders can look to buy Lion Biotechnologies off weakness to anticipate that breakout and simply use a stop that sits right below either its 20-day at $9.30 or its 200-day at $9.04 a share. One can also buy this stock off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

TherapeuticsMD

Image placeholder title

One final under-$10 health care player that's starting to move within range of triggering a big breakout trade is TherapeuticsMD (TXMD) - Get Report, which manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter, vitamins, and cosmetics. This stock has been blazing a trail to the upside over the last six months, with shares sharply higher by 98%.

If you take a glance at the chart for TherapeuticsMD, you'll notice that this stock has been uptrending incredibly strong over the last six months, with shares moving higher from its low of $4 to its recent high of $8.60 a share. During that uptrend, this stock has been making mostly higher lows and higher highs, which is bullish technical price action. Shares of TherapeuticsMD spiked higher on Wednesday right off its 20-day moving average of $8.05 a share. That spike is now quickly pushing this stock within range of triggering a big breakout trade above some key near-term overhead resistance levels.

Traders should now look for long-biased trades in TherapeuticsMD if it manages to break out above some key near-term overhead resistance levels at $8.34 to $8.40 a share and then above its 52-week high of $8.60 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.15 million shares. If that breakout triggers soon, then this stock will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $9 to $10, or even $11 a share.

Traders can look to buy TherapeuticsMD off weakness to anticipate that breakout and simply use a stop that sits right below its 20-day at $8.05 or just below its 50-day at $7.60 a share. One can also buy this stock off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

-- Written by Roberto Pedone in Delafield, Wis.

Follow Stockpickr on Twitter and become a fan on Facebook.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.